CardioInsight Technologies is a healthcare startup founded in 2006 that specializes in non-invasive 3D imaging of the heart's electrical activity. The company's slogan, "Non-invasive 3D imaging of heart's electrical activity for precise treatment of arrhythmias and heart failure," reflects its focus on innovative technology for cardiac care.
CardioInsight is advancing a groundbreaking technology called Electrocardiographic Mapping (ECM) that non-invasively creates 3D images of the heart's electrical activity. These images assist physicians in more accurately treating certain heart conditions such as arrhythmias and congestive heart failure. ECM non-invasively produces real-time, whole heart images by merging body surface electrical data with 3D anatomical data from CT scans. The CardioInsight system reconstructs and visualizes 3D images and other valuable metrics of cardiac electrical activity as if measured directly from the heart's surface. This precise imaging capability and its potential to guide therapy for cardiac arrhythmias and congestive heart failure have been demonstrated in over 260 patient studies sponsored by the company.
The most recent investment in CardioInsight was a $15.00M Series C investment on 11 November 2013, led by West Capital Advisors, Draper Triangle, and Medtronic.
Overall, CardioInsight Technologies' pioneering approach to non-invasive cardiac imaging and its strong support from reputable investors position it as a compelling player in the healthcare technology space. The company's ability to merge cutting-edge technology with practical clinical applications makes it an attractive prospect for further investment and potential market disruption.
